Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront ...

French biotech firm Valneva said on Thursday its COVID-19 vaccine candidate was efficient as a booster for people who had received the same shot as an initial vaccination.

Summary. Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva’s main ...

French drugmaker Valneva said on Wednesday it will conduct a trial about the use of its COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.

Valneva’s chief medical officer Juan Carlos Jaramillo said: “We reiterate our support for the precautionary measures that have been taken as well as our commitment to continue monitoring all ...

Valneva’s VALN shares surged 24.3% on Nov 10, after the company announced that it has entered into an advance purchase agreement (APA) with the European Commission (EC) for the supply of its ...

Valneva SE is a French biotechnology company specializing in developing and commercializing vaccines. We expect approval of two attractive vaccine candidates targeting Chikungunya and Lyme disease ...

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three ...

Shares of Valneva VALN have plunged 52.9% in the trailing 12 months compared with the industry’s 33.8% decline. This substantial decline was caused by the revision of the advance purchase ...

Saint-Herblain (France), November 9, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of ...